APCR Issues Statement on COVID-19

Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Executives On The Move: Operations Change At Khondrion And A Promotion At Grunenthal

Thu, 12/19/2019 - 2:41am

Khondrion BV, developer of therapies for mitochondrial disease, has appointed a former Novartis SVP as COO, and pain and inflammation...

      Related Stories 

Patent Pool Strikes Deals with Cipla, Pfizer For New HIV, TB Drugs

Wed, 12/18/2019 - 7:09pm

The Medicines Patent Pool, a UN-backed public health organization, has announced deals with two major global pharma firms aimed at...

      Related Stories 

Astellas, Seattle Genetics Break Ground With US ADC Approval

Wed, 12/18/2019 - 7:03pm

Co-developers gain nod for novel antibody-drug conjugate that provides new option for patients with advanced form of bladder cancer.

      Related Stories 

Tech Transfer Roundup: MD Anderson Inks Set Of IO Deals Covering US, UK, Japan, China

Wed, 12/18/2019 - 1:09pm

Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by...

      Related Stories 

Can Low LSD Doses Address Alzheimer’s Disease?

Wed, 12/18/2019 - 7:18am

The CEO of Eleusis tells Scrip how the privately held biotech plans to progress low-dose lysergic acid diethylamide (LSD) to...

      Related Stories 

FDA Panel Tentative Yes To AZ’s Lynparza In Pancreatic Cancer

Wed, 12/18/2019 - 6:04am

Lynparza doubled PFS in metastatic patients with germline mutations in BRCA but the FDA usually wants to see OS data...

      Related Stories 

First Generic Of Gilead’s Biktarvy In India Debuts

Tue, 12/17/2019 - 10:20pm

Hetero launches cut-price version of Gilead’s Biktarvy in India but 20 other India-based firms also hold licenses for the product...

      Related Stories 

Podcast: Significant Approvals, Diabetes And NASH In India, Japan M&A

Tue, 12/17/2019 - 3:37pm

Join the Asia-based content team for Scrip and the Pink Sheet for their first podcast as they take a look at...

      Related Stories 

Alnylam Seeking Lumasiran Approvals Soon, But Has Two Rivals On Its Heels

Tue, 12/17/2019 - 3:13pm

Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing...

      Related Stories 

Intercept’s Early NASH Efforts Will Stress Advanced Fibrosis

Tue, 12/17/2019 - 12:12pm

Intercept said its commercial groundwork in NASH centered on identifying doctors who treat patients with advanced fibrosis and talking to...

      Related Stories 

Pipeline Watch: The ASH Bumper Edition

Tue, 12/17/2019 - 7:26am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

GSK Files Its BCMA Drug In Multiple Myeloma

Tue, 12/17/2019 - 7:05am

GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate...

      Related Stories 

Axsome Soars After Depression Trial Success

Tue, 12/17/2019 - 6:44am

Axsome is set to file for approval in the second half of 2020.

      Related Stories 

Wave Crashes Down On Duchenne Fail

Tue, 12/17/2019 - 4:37am

Having spectacularly failed even to match Sarepta’s Exondys 51 in the restoration of dystrophin in Duchenne muscular dystrophy patients, Wave's...

      Related Stories 

EU Approval Delay for Janssen’s Spravato?

Tue, 12/17/2019 - 2:57am

The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive...

      Related Stories 

Roche/Spark Deal Clears FTC In A Sigh Of Relief For Pharma Dealmakers

Mon, 12/16/2019 - 3:31pm

US Federal Trade Commission says it conducted an "exhaustive" 10-month investigation and determined Roche would not have incentive to delay...

      Related Stories